Skip to content
value.today

Bluejay Diagnostics, Inc.

BJDX
$5 Mmarket cap on Aug 1, 2026+150.0% since Jan 2024
Compare
World rank
#26,867
Revenue
—
For year ending December-2025
Net income
$-7 M
SEC filing
Employees
6
As of March 2, 2026
SEC filing

Bluejay Diagnostics, Inc. in brief

Bluejay Diagnostics, Inc. is a listed company in the Healthcare sector, based in Acton, Massachusetts, USA. Its market value was $5 M on 1 August 2026, which makes it the 26,867th largest listed company in the world and the 4,401st largest in the USA on this site. It employs about 6 people and Indranil Dey is its chief executive. Its shares trade under the symbol BJDX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform, which consists of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. We have completed the pre-clinical development of the Symphony analyzer. During 2026, we transferred the knowledge, technology and process underlying the production of the Symphony cartridges from the original developer and outside supplier, Toray Industries, to a contract manufacturing facility with FDA certification run by Sanyoseiko. We are also working with Sanyoseiko to modify the manufacturing process of the Symphony cartridges to address certain technical issues to bring Symphony to a level consistent with necessary performance and quality requirements for regulatory submission. To achieve our plan, we expect to need to raise at least $20 million of further capital by the end of the 2027 fiscal year, which we hope to do in various tranches.

From the company's annual report filed with the US SEC: read the report

Bluejay Diagnostics, Inc. timeline

2 events, 2017–2021
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 12 November 2021; shares registered for exchange trading on 5 November 2021.

Events of Bluejay Diagnostics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$2 M$4 M$6 M$9 M2023202420252026

World rank over time

▲ up 8,164 places since 2022
2022-12-25: #31772#31,77220222023-07-30: #32150#32,15020232024-01-05: #33480#33,48020242026-03-08: #13767#13,76720262026-08-01: #23608#23,6082026

Rank in USA: #5,636 (Dec 2022) · #5,498 (Jul 2023) · #4,726 (Jan 2024) · #2,510 (Mar 2026) · #4,124 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.8×
Free cash flow yield
-124.4%
Net margin
—
Operating margin
—
Return on equity
-114.5%
Liabilities / assets
16.0%
R&D / revenue
1660.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-1M—FY20Fiscal year ending Dec 2021: revenue —, net income $-3M—FY21Fiscal year ending Dec 2022: revenue $0M, net income $-9M$0MFY22Fiscal year ending Dec 2023: revenue —, net income $-10M—FY23Fiscal year ending Dec 2024: revenue —, net income $-8M—FY24Fiscal year ending Dec 2025: revenue —, net income $-7M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-7M$-7M—
Dec 2024——$-7M$-8M—
Dec 2023——$-10M$-10M—
Dec 2022$0M—$-9M$-9M-3720.0%
Dec 2021——$-3M$-3M—
Dec 2020——$-1M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-6M$0M$-6M$-15.25—
Dec 2024$-8M$0M$-8M$-456.75—
Dec 2023$-8M$1M$-9M$-3631.48—
Dec 2022$-8M$1M$-9M$-9.22—
Dec 2021$-4M$0M$-4M$-0.41—
Dec 2020$-1M——$-0.37—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue —, net income $-2M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Bluejay Diagnostics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-7 M
Net income
$-7 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$1 M
Total equity
$6 M

As of December-2025

Top 14 institutional investors in Bluejay Diagnostics, Inc.#

As of Sep 30, 2026
14 institutions held 210,058 shares (about 18.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 18.8%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 14 largest institutional investors in Bluejay Diagnostics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Citadel Advisors LLC54,764New4.90%$0 MNov 16, 2026
2Jane Street Group, LLC43,895New3.93%$0 MNov 12, 2026
3Geode Capital Management, LLC39,602New3.55%$0 MNov 6, 2026
4Susquehanna International Group, LLP27,684New2.48%$0 MNov 16, 2026
5StoneX Group Inc.17,828New1.60%$0 MNov 3, 2026
6Virtu Financial LLC12,027New1.08%$0 MNov 17, 2026
7Vanguard Fiduciary Trust Co10,2250 (0.00%)0.92%$0 MNov 13, 2026
8Tower Research Capital LLC (TRC)2,933+1,026 (+53.80%)0.26%$0 MNov 16, 2026
9UBS Group AG596New0.05%$0 MNov 10, 2026
10SBI Securities Co., Ltd.302New0.03%$0 MOct 22, 2026
11L1 Global Manager Pty Ltd1200 (0.00%)0.01%$0 MNov 16, 2026
12Robinhood Markets, Inc.71—0.01%$0 MNov 18, 2026
13Jpmorgan Chase & Co10New0.00%$0 MNov 12, 2026
14Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Bluejay Diagnostics, Inc.#

2 funds hold shares worth $0 M (about 2.3% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Bluejay Diagnostics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC25,155$0 M2.3%<0.01%+183%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC183$0 M0.02%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Bluejay Diagnostics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$122 K
6 purchases, 6 insiders
Sold, 12 months
$49 K
1 sale, 1 insider
Net, 12 months
$73 K
open market only
Insiders on file
9
since
$97 K-$49 K$0Dec 2023: bought $3 K (2 trades), sold $0 (0 trades)Dec 23Mar 2026: bought $25 K (5 trades), sold $0 (0 trades)MarJul 2026: bought $97 K (1 trades), sold $49 K (1 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Bluejay Diagnostics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Indranil DeyPresident and CEO, DirectorGrant or award+28,000——40,522Form 4
filed HRT Financial LP10% ownerSell-34,938$1.400$49 K92,055Form 4
filed HRT Financial LP10% ownerBuy+64,047$1.510$97 K126,993Form 4
filed Donald R. ChaseDirectorBuy+12,500$2.000—12,525Form 4
filed Douglas Clark WurthDirectorBuy+12,500$2.000—12,608Form 4
filed Indranil DeyPresident and CEO, DirectorBuy+12,500$2.000—12,522Form 4
filed Svetlana DeyDirectorBuy+12,500$2.000$25 K12,501Form 4
filed Fred S. ZeidmanDirectorBuy+12,500$2.000—12,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Bluejay Diagnostics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
77,889
51.6% of shares · 1.01 days to cover
Buybacks, Q3 2026
$0M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
Bluejay Diagnostics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0M
Q3 2025Q3 2026$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$0.1M

Trading halts

  • 2026-11-03 00:50 UTC, code T3, resumed 14:00 UTC
  • 2026-01-29 00:50 UTC, code T3, resumed 14:00 UTC
  • 2025-10-09 19:20 UTC, code LUDP, resumed 19:30 UTC
  • 2025-10-09 19:15 UTC, code LUDP, resumed 19:20 UTC
  • 2025-04-07 17:41 UTC, code LUDP, resumed 17:46 UTC

Fails to deliver

  • : 2,116 shares at $0.59
  • : 73,765 shares at $0.81
  • : 70,033 shares at $0.81
  • : 1,000 shares at $0.76
  • : 5,605 shares at $0.91

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Bluejay Diagnostics, Inc. scorecard#

Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-15.25 vs -456.75Diluted EPS -15.25 in fiscal 2025 against -456.75 the year before (report's currency).
    • ✗Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$1 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-117.0%-117.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.87 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Bluejay Diagnostics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Bluejay Diagnostics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue———249——
Cost of revenue———200——
Gross profit———49——
Research and development3,0463,4725,7154,1521,148527
Selling, general and administrative——283451——
Selling and marketing—8.328345129073
General and administrative3,9073,6904,3134,7631,792596
Operating expenses6,9537,17010,3119,3673,2301,196
Operating income−6,953−7,170−10,311−9,318−3,230−1,196
Interest and finance income98146165———
Interest expense and finance costs0.8823——6.459
Net interest income————−367−27
Other non-operating income (expense)104−54835721−25838
Net income including minority interests————−3,488−1,158
Net income attributable to shareholders−6,848−7,718−9,954−9,297−3,488−1,158
Earnings per share, basic-15.25-456.75r-3,631.48r-9.22r-0.41-0.37
Earnings per share, diluted-15.25-456.75r-3,631.48r-9.22r-0.41-0.37
Shares, weighted average (basic)0.40.0r0.0r1.0r8.5—
Shares, weighted average (diluted)0.40.0r0.0r1.0r8.53.1
Balance sheet
Cash and cash equivalents5,1654,3022,20910,11519,048912
Inventory—————85
Other current assets2765977471,6731,61361
Current assets5,4644,8993,22111,78820,6601,058
Property, plant and equipment1,5341,5131,2861,232337459
Right-of-use (leased) assets113210333466——
Total assets7,1196,6574,86913,52121,0191,517
Accounts payable214145491636296375
Current liabilities1,1198101,7711,640637—
Lease liabilities (non-current)20109190324——
Total liabilities1,1449281,9741,9806371,845
Retained earnings−41,517−34,669−26,951−16,997−7,695−4,206
Shareholders' equity5,9755,7292,89511,54120,382−4,206
Total liabilities and equity7,1196,6574,86913,52121,0191,517
Shares outstanding0.2r0.1r0.0r1.0r203.1
Cash-flow statement
Depreciation and amortization———157146157
Share-based compensation0.020189433683.7
Cash from operating activities−6,054−7,821r−8,314−7,742−4,367−509
Capital expenditure−174−307−704−1,199−24—
Cash from investing activities−174−307−704−1,199−24—
Shares issued8,34712,0691,591———
Cash from financing activities7,09010,221r1,1128.122,5261,325
Change in cash———−8,93318,135816
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Bluejay Diagnostics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 8 · Unregistered share sale 4 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 2

Bluejay Diagnostics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Bluejay Diagnostics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$1 MNo. 3Under $2 million1equitySEC
Apr 2019$2 MNo. 2Under $2 million6equity, optionsSEC
Mar 2017$2 MNo. 1Under $2 million9equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Bluejay Diagnostics, Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2023, most often on health issues.

Lobbying, 2023
$30 K
#1,311 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2023
2026 so far
—
  • Health Issues1 report

Lobbying firms hired in 2023

PLATINUM ADVISORS DC, LLC $30 K

Bluejay Diagnostics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2023$30 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Bluejay Diagnostics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Bluejay Diagnostics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $175 K a year.

Certified, FY2026
1
#1,919 among companies on value.today
Worker positions
1
Median wage offered
$175 K
a year, full-time
Applications filed
1
Bluejay Diagnostics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
CORPORATE CONTROLLERTreasurers and Controllers1$175 K

Where: Acton, MA 1

Bluejay Diagnostics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$175 K1
FY202511$120 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Bluejay Diagnostics Inc

How Bluejay Diagnostics, Inc. compares in Healthcare

  • Market cap$5 M · higher than 4% of 2,013
  • Price / book0.8× · lower than 86% of 1,245
  • FCF yield-124.4% · higher than 6% of 835
CompanyMarket capP/ENet marginRev. growth
Bluejay Diagnostics, Inc.🇺🇸$5 M———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 2, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Bluejay Diagnostics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Bluejay Diagnostics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Bluejay Diagnostics, Inc.? Suggest a correction